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Purpose:  To compare the efficacies and safeties of Meditoxin® (Medy-Tox, Korea) and Botox® in the treatment of 
essential blepharospasm.
Methods: We performed a double-blind, randomized, comparative trial comparing Meditoxin® and Botox® for 
treatment of blepharospasm in 60 patients from the intention-to-treat (ITT) population and 52 patients from the 
per-protocol (PP) population. We analyzed the improvements in severity of spasm (SS) at four weeks post-injection 
as a primary efficacy outcome. Changes in eyelid closing force (CF) and functional visual status (FVS) after in-
jection were analyzed for secondary efficacy outcomes, and adverse effects were demonstrated for the safety 
evaluation.
Results: Improvement in SS was noted in 90.3% of the Meditoxin® group and 86.2% of the Botox® group. There were 
no significant differences between treatment groups in the changes of CF and FVS post-injection (p>0.05). Since 
the lower limit of the 95% confidence interval (-1.76% for ITT, -1.64% for PP) was over the -15% threshold, we 
determined that Meditoxin® was not inferior to Botox® in either the ITT or PP populations. Adverse effects developed 
in 16.1% of the Meditoxin® group and 27.6% of the Botox® group, but no serious adverse events were found in either 
group. 
Conclusions: Meditoxin® and Botox® were comparable in efficacy and safety in the treatment of essential blepha-
rospasm.
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Botulinum toxin type A (BTX-A) is currently the first treat-
ment of choice for benign essential blepharospasm due to its 
safety and efficacy. Scott and coworkers first used isolated 
BTX-A to treat blepharospasm over 20 years ago.1 Since then, 
a number of BTX-A preparations have been approved in 
different countries. Currently, there are four different BTX-A 
preparations available on the market in one or more countries, 
all of which contain Botox® (Allergan Inc., Irvine, CA, USA),2-5 
Dysport (Ipsen Ltd, Slough, UK),6-8 Xeomin (Merz Pharma-
ceuticals, Frankfurt am Main, Germany)9 and Prosigne (Lan-
zhou Biological Products, China).10 Several studies have com-
pared the different formulations of BTX-A for the treatment 
of blepharospasm with regard to duration of the effect or ad-
verse events.2-11 Recently, equivalent efficacies were reported for 
Xeomin and Prosigne with Botox®.9, 10 
Meditoxin® (Medy-Tox, Seoul, Korea another name: Neu-
ronox®) was introduced for the treatment of BTX-A and is 
currently available in Korea. In a murine model, a dose-response 
curve and time course of recovery for Meditoxin® (Neuronox® 
in this study) were established.12 Botox® and Meditoxin® 
produced a nearly equivalent decrease in muscle force (30- 
90%) at four days after toxin injection, and the muscle force 
had recovered from the effects of both toxin preparations at 
28 days post-injection.12 As there was little information about 
the clinical efficacy and safety of Meditoxin®, we set out to 
perform a double-blind, randomized, controlled clinical study 
designed to compare Meditoxin® and Botox® in the treatment 
of essential blepharospasm. This is the first report to compare 
the treatment efficacies and safeties of Meditoxin® and  Botox®. 
In addition, we qualitatively evaluated the presence and absence 
of BTX-A antibodies in patients after the disappearance of the 
therapeutic effects in both Botox® and Meditoxin® groups.
Materials and Methods
Study design
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Table 1. Scoring definition for severity of spasm, eyelid closing 
force and the functional visual status
Severity of spasm
Grade
0
1
2
3
4
Definition
No spasm
Mild spasm at stimulation only
Visible spasm without impairment of daily life
Visible spasm with impairment of daily life
 Severe Spasm with impairment of daily life
Eyelid closing force
Grade
1
2
3
4
Definition
Flaccid
Overcome with minimum resistance
Overcome with moderate resistance
Normal strength
Functional visual status
Grade
1
2
3
4
5
6
Definition
Functional blindness
Dependent; unable to go out alone
Poor function; unable to watch TV, read or drive
Moderate function; unable to read but able to work
Inconvenience; intermittent discomfort but able to drive, work
Normal
Fig. 1. Flow of patients throughout the trial. N, number of patients 
with data. 
This double-blind randomized, prospective, multi-center, 
phase III, comparative clinical trial was conducted ethically 
and scientifically in accordance with KGCP (Korean Good 
Clinical Practice) guidelines and the principles of the Decla-
ration of Helsinki. The study protocol, protocol amendments, 
patient information and informed consent forms were reviewed 
and approved by the KFDA (Korean food drug administra-
tion) and the institutional review board at each institution site 
prior to study initiation. All participants in the study signed a 
consent form approved by the institutional review board. 
Study population
All included patients, between the ages of 18 and 75, had 
confirmed diagnoses of bilateral essential blepharospasm. The 
patients were recruited from two botulinum toxin clinics 
(Yonsei University and Chung-Ang University, Seoul, Korea) 
between June 7, 2005 and September 27, 2005. Patients were 
not included in the study if they had undergone either myec-
tomy or neurectomy, had received anti-spastic, muscle relaxant 
medication within one month of study entry, had been injected 
previously with BTX-A within three months of study entry, or 
had any muscle disorder. Women with a positive urine pre-
gnancy test, or who were pregnant or lactating, were also ex-
cluded from the study. In addition, patients who had previously 
shown hypersensitivity to BTX-A were not eligible for inclusion 
in the study. 
Randomization and assessor blinding
At each center, eligible patients were randomly assigned to 
either the Meditoxin® or Botox® group according to a computer- 
generated randomization schedule, and all of the randomized 
patients were part of the intention-to-treat (ITT) population. 
A pack containing one vial of study medication was allocated 
to each patient. Investigators were blinded throughout the 
study to the treatment dose and type of treatment. A double- 
blind method was maintained until the results were analyzed. 
The per-protocol (PP) population excluded patients who violated 
the protocol and did not complete the study.
Study medications and injections
Each vial of Botox® (Allergan Inc., Irvine, CA, USA) and 
Meditoxin® (Medy-Tox, Seoul, Korea) contained 100 U of 
BTX-A, 0.5 mg of serum albumin, and 0.9 mg of sodium 
chloride in a sterile vacuum-derived form without preservatives. 
The Meditoxin® vials were identical to the Botox® vials, and 
all vials were reconstituted with 2.0 mL of 0.9% sterile, non- 
preserved saline solution for a final dilution of 5 U/0.1 mL. 
Two independent investigators blindly prepared and admini-
stered the BTX-A. The dose of BTX-A per injection site ranged 
from 2.5 U to 5 U, and the location, number of injection sites, 
and total dose of each treatment were maintained throughout 
the study. When the patient was treated with BTX-A for the 
first time, the dose per injection was 1.25 to 2.5 U. The total 
dose was limited to 60 U per person. Using a 30-gauge needle, 
injections were angled away from the center of the lid to 
reduce the risk of spread into the levator muscle. Injection 
sites included the upper medial and lateral eyelid margins, 
lower lateral lid margins and above the eyebrow. 
Outcome Measures
The severity of spasm (SS) was graded clinically from grade 
0 to 4 (Table 1).13,14 The primary efficacy outcome was assessed 
as the number (%) of patients with an improvement in SS of 
more than one grade at four weeks post-injection. Secondary 
efficacy outcome measures included the change in SS scores 
from baseline, closing force of eyelids (CF)13 and functional 
visual status (FVS)14 at four weeks post-injection (Table 1). 
The duration of action (days), which was the time interval 
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Fig. 2. Distribution of severity of spasm scores (grade 0-4) before 
injection and at four weeks after injection in both Meditoxin® and 
Botox® treatment groups. 
M pre, Meditoxin® group before injection; M post, Meditoxin® group
at four weeks post-injection; B pre, Botox® group before injection; B
post, Botox® group at four weeks post-injection.
Table 2. Comparison of demographics and clinical characteristics of the patients in the intention-to-treat (ITT) group
Meditoxin®  
(n=31)
Botox®  
(n=29) p
Age 61.2±9.1 62.2±7.0 0.665*
F : M 25 : 6 25 : 4 0.732†
No. of previous Botox® injection 
L : H group
9.9±9.9
13 : 13
8.3±6.8
15 : 11 0.492
*
SS pre-injection
   No. patients with SS 4
3.5±0.6
17 (55%)
3.4±0.8
16 (55%)
0.734*
0.377†
CF pre-injection
   No. patients with CF 4
3.7±0.5
23 (74%)
3.8±0.5
23 (79%)
0.658*
0.872†
FVS pre-injection
   No. of patients with grade 3/4/5/6
4.6±0.9
5/ 9/ 12/ 5
5.0±0.9
4/ 1/ 15/ 9
0.074*
0.041†
Total amount of BTX-A injection 41.5±7.4 41.9±6.4 0.818*
Data are shown as mean±SD, except for several categorical values (number of patients). 
* t-test (age), * Mann-Whitney U test (other data); † χ2 test were used for statistically analysis. 
BTX-A=botulinum toxin A; CF=eyelid closing force; F=female; FVS, functional visual status; H group=patients with more than five BTX-A 
injections; L group=patients with five BTX-A injections or less; M=male; No=number; SS=severity of spasm.
between injection and the moment that the patient felt the 
need for retreatment, was also subjectively assessed based on 
the patients’ self-reports at the time of retreatment. Patients in 
the PP populations were assigned to a group according to the 
BTX-A application number; patients with five BTX-A injec-
tions or less were classified as the L group and those who had 
more than five injections were classified as the H group. In both 
the L and H groups, both primary and secondary efficacy out-
comes were compared between the Meditoxin® and Botox® 
groups. 
To evaluate safety, adverse effects were documented and 
classified as either not serious or serious. Serious side effects 
included debilitating symptoms such as an obscured visual axis 
lasting for more than three months. 
BTX-A antibody testing was performed using a mouse dia-
phragm assay.15 Serum samples were collected before injection 
and after the disappearance of the BTX-A effect. Blood samples 
were refrigerated at -20℃ prior to analysis for Botulinum toxin 
antibodies (ABS). Results of this qualitative bioassay were 
reported as either positive or negative. 
Statistical Analysis
The efficacy and safety outcomes were analyzed in both 
ITT and PP populations. Change in SS scores, CF and FVS 
were evaluated and compared within and between groups 
using a t-test. Fisher’s exact test or χ2 tests were performed to 
compare categorical values between groups such as the number 
of patients with improvement in SS, and adverse effects. A p 
value of less than 0.05 was considered statistically significant. 
To demonstrate that Meditoxin® is not inferior to Botox®, 
a non-inferiority trial based on primary efficacy outcomes was 
performed. After study completion, a two-sided 95% confi-
dence interval on primary efficacy outcomes between the two 
agents was constructed. The non-inferiority margin was defined 
as 15% (Δ=0.15), and the test drug was considered non-inferior 
if the lower limit of the confidence interval for the difference 
between the two drugs was greater than -Δ. 
Results
A total of 60 patients were enrolled in the study, with 31 
patients randomly assigned to Meditoxin® treatment and 29 
patients to Botox® treatment (Fig. 1). Of the 60 patients ran-
domized to treatment (ITT population), five patients in the 
Meditoxin® group and three patients in the Botox® group 
were excluded from the study (Fisher’s exact test, p=0.708). 
Therefore, there were 26 patients in both the Meditoxin® and 
Botox® PP groups. Six patients completed the study, but violated 
the protocol, and another two patients did not follow-up for 
unrelated causes. Three patients had a previous Botox® injec-
tion within three months of study entry, one was over 75 years 
of age, and two received muscle relaxants during the study 
period. Of these eight patients, none withdrew from treatment 
due to lack of efficacy. 
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Table 3. Comparison of primary and secondary efficacy outcomes between the Meditoxin® and Botox® treatment groups
Meditoxin® Botox®  p
Primary efficacy outcome in ITT 
n (%) 28/31 (90.3%) 25/29 (86.2%) 0.702*
95% CI (79.9-100) (73.6-98.7)
Secondary efficacy outcome in PP
SS at 4 weeks 1.9±1.0 2.0±1.2 0.635† 
SS pre-post 1.6±1.0 1.3±0.9 0.215†
CF pre-post 2.7±0.5 2.8±0.5 0.792†
FVS pre-post 0.3±0.9 0.1±0.6 0.398†
SS 0 or 1 at 4 week 8/26 (30.8%) 6/26 (23.1%) 0.587†
≥2 scores of SS at 4 weeks 11/26 (42.3%) 8/26 (30.7%) 0.387†
Duration of action (days) 136.8±33.8 138.7±28.2 0.835†
Data are shown as mean±SD except several categorical values (number of patients). 
* χ2 test; † Mann-Whitney U test were used for statistical analysis. 
BTX-A=botulinum toxin A; CF pre-post=difference in mean scores of eyelid closing force between pre-injection and at four weeks after 
injection; CI=confidence interval; FVS pre-post=difference in mean scores of functional visual status between pre-injection and at four weeks 
after injection; ITT=intention-to-treat; SS pre-post=difference in mean scores of severity of spasm between pre-injection and at four weeks 
after injection; SS 0 or 1 at 4 weeks=patients with SS score of 0 or 1 at four weeks post-injection; PP=per-protocol; ≥2 scores of SS=patients 
with improved 2 or more scores in SS at four weeks post-injection.
Table 4. Adverse effects following Meditoxin® and Botox®
injections
Meditoxin® Botox®  p
Ptosis 2 3
Dry eye 0 1
Ocular foreign body sensation 2 0
Ocular irritation 1 0
Headache 0 1
Eyelid edema 0 2
Pain 0 1
Total 5 /31 
(16.1%)
8/29 
(27.6%)
0.282
There were no significant differences in the mean age, sex, 
number of previous Botox® injections, baseline SS, CF and 
FVS scores, and total amount of BTX-A injected between the 
Meditoxin® and Botox® groups (Mann-Whitney U test, χ2 test, 
p>0.05, Table 2).  
Efficacy and safety outcomes were evaluated in both the 
ITT and PP populations. In the ITT group, the SS score (before 
injection; mean±SD, 3.5±0.6) significantly improved at four 
weeks post-Meditoxin® injection (mean±SD, 1.5±0.9) (Wil-
coxon signed-rank test, p<0.001). In the Botox® group, the 
baseline SS score (before injection; mean±SD, 3.4±0.7) also 
improved significantly at four weeks post-injection (mean± 
SD, 1.3±1.1) (Wilcoxon signed-rank test, p<0.001). This sig-
nificant improvement was also found in the PP population for 
both the Meditoxin® and Botox® groups (Wilcoxon signed- 
rank test, p<0.001) (Fig. 2). 
The number (%) of patients with improvement in SS (primary 
efficacy outcome) and the change in scores from baseline at 
four weeks post-injection for the SS, CF and FVS scores were 
not different between the Meditoxin® and Botox® groups in 
the analysis of both the ITT and PP populations (Table 3). Also, 
the duration of action was similar following Meditoxin® and 
Botox® injections (Mann-Whitney U test, p=0.835). For the 
non-inferiority trial on primary efficacy outcome, Meditoxin® 
was not inferior to Botox® in either the ITT or PP populations, 
as the lower limit of the 95% confidence interval (-1.76% for 
ITT, -1.64% for PP) was over the -15% threshold. 
In comparing the outcomes in each L and H group, there 
were no significant differences in the primary or secondary 
efficacy outcomes between the Meditoxin® and Botox® groups 
(p>0.05, data not shown). The number of patients with an SS 
score of 0 or 1 at four weeks post-injection was not different 
between the Meditoxin® and Botox® groups in either the L 
(5/13 versus 2/15, Fisher’s exact test, p=0.201) or H (3/13 versus 
4/11, p=0.651) groups. In addition, the number of patients with 
SS scores that improved by two points or greater was not di-
fferent between the two groups in either L (6/13 versus 4/15, 
p=0.433) or H (5/13 versus 4/11, p=1.000) group.
Using a multiple regression model, none of the evaluated 
factors, including sex (p=0.917), age (p=0.516), L or H group 
(p=0.565), past illness history (p=0.594), baseline SS score 
(p=0.159), or total injection dose (p=0.857), influenced the 
primary efficacy outcome. 
Adverse effects were evaluated in the ITT population (Table 
4). The frequency of adverse effects was not different between 
the Meditoxin® and Botox® groups (χ2 test, p=0.282). All of 
the adverse effects were mild and temporary, and no serious 
adverse effects occurred during the study period. 
Botulinum toxin antibody testing was performed in all 60 
patients during their initial visits, and in 58 of the patients at 
the last visit. None of the patients showed positive antibody 
test results. 
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Discussion
Botulinum toxin A has been successfully used to treat 
blepharospasm for more than 20 years and is considered the 
treatment of choice. Meditoxin® was recently approved by 
the KFDA and is widely used in Korea for the treatment of 
wrinkles, essential blepharospasm and hemifacial spasms. 
Since one Meditoxin® vial is equivalent to one Botox® vial in 
terms of units of BTX-A, equivalent units of Meditoxin® with 
Botox® can be used. In our study, we used a 1:1 ratio of Medi-
toxin® and Botox® and found equivalent clinical efficacy with 
a significant reduction infunctional impairment in patients 
with essential blepharospasm. 
This is the first double-blind, randomized, phase III study 
comparing Meditoxin® and Botox® in the treatment of essen-
tial blepharospasm. In this study, we demonstrated that Medi-
toxin® was similar to Botox® for short-term primary and secon-
dary efficacies. Khoo et al. reported similar results for the scores 
of mean spasm severity and eyelid closure force, which were 
3.2±0.8 and 3.2±0.6 before injection and 0.9±0.5 and 1.1±0.6 
after injection, respectively.13 The mean duration of action was 
similar in the four months following injection in both groups. 
In addition, we found that Meditoxin® was not inferior to 
Botox® in our analysis of non-inferiority. 
The adverse effects found in our study were similar to those 
previously reported in the literature.16,17 No differences were 
noted in the frequency of adverse effect between the Medi-
toxin® (16.1%) and Botox® (27.6%) groups. There were no 
serious, long-standing adverse effects following Meditoxin® 
injections. The adverse effects that did manifest in the Medi-
toxin® group were ptosis, foreign body sensation and irritation, 
all of which were mild and short-lived. Ptosis may result from 
local effusion of a drug to the levator aponeurosis, and is not 
specific to this type of drug. No adverse effects were apparent 
when examining vital signs or the results of clinical laboratory 
tests. 
There is concern that botulinum toxin therapy may become 
ineffective due to the formation of antibodies against BTX-A. 
Usually this phenomenon appears some years after using 
BTX-A in higher doses for treatment of cervical dystonia.18 
Botulinum toxin antibodies were not found in either the Me-
ditoxin® or Botox® groups in our study, maybe because we did 
not use the toxin in high enough concentrations to induce an-
tibody formation, or because the follow-up duration was not long 
enough. 
This controlled study confirmed in a double-blind, rando-
mized manner that Meditoxin® is a new drug that is both effec-
tive and safe for the treatment of essential blepharospasm. We 
found that Meditoxin®, when used at the same dose as Botox®, 
was sufficient to decrease the degree of muscle spasm and to 
relieve symptoms, and that the duration of effect was similar 
to that of Botox®. In conclusion, Meditoxin® can be safely used 
as an alternative to Botox® treatment at a 1:1 equivalence.
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